Santen CEO appointed to OccuLogix Board
OccuLogix Inc. has appointed Adrienne L. Graves, PhD, president and CEO of Santen Inc., to its board of directors.
May 3
- Fort Lauderdale, FL - OccuLogix Inc. has appointed Adrienne L. Graves, PhD, president and CEO of Santen Inc., to its board of directors.
The healthcare company, which is involved in bringing innovative and evidence-based medical therapies to market, chose Dr. Graves because of her experience with clinical, regulatory, and commercial development of products within the ophthalmic industry. Under her leadership, Santen's research and development team successfully developed and obtain FDA approval for three ophthalmic products in major therapeutic areas.
"On behalf of the staff and board of OccuLogix, I would like to welcome Dr. Graves," said Elias Vamvakas, OccuLogix's chairman and CEO. "We all look forward to working with Adrienne and benefiting from her valuable involvement in the development of the RHEO procedure."
Dr. Graves is the author of more than 30 research papers. She is a member of a number of professional associations, including the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, the American Glaucoma Society, and Women in Ophthalmology. In addition, Dr. Graves co-founded Ophthalmic Women Leaders with Marguerite McDonald, MD.
